{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:46:28Z","timestamp":1762004788278},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,20]]},"DOI":"10.4103\/0366-6999.179803","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T08:47:07Z","timestamp":1460018827000},"page":"992-999","source":"Crossref","is-referenced-by-count":10,"title":["Hybrid Therapy Regimen for Helicobacter Pylori Eradication"],"prefix":"10.1097","volume":"129","author":[{"given":"Zhi-Qiang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210129","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"key":"R2-17-20210129","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection \u2013 The Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"R3-17-20210129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"R4-17-20210129","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.3748\/wjg.v20.i30.10338","article-title":"Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance","volume":"20","author":"Molina-Infante","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R5-17-20210129","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.dld.2014.08.038","article-title":"Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients","volume":"46","author":"Song","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R6-17-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1523-5378.2011.00828.x","article-title":"Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days","volume":"16","author":"Hsu","year":"2011","journal-title":"Helicobacter"},{"key":"R7-17-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-17-20210129","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.3748\/wjg.v21.i36.10435","article-title":"Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial","volume":"21","author":"Chen","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R9-17-20210129","doi-asserted-by":"crossref","first-page":"10234","DOI":"10.3748\/wjg.v21.i35.10234","article-title":"Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication","volume":"21","author":"Hwang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R10-17-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.gastro.2013.03.050","article-title":"Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance","volume":"145","author":"Molina-Infante","year":"2013","journal-title":"Gastroenterology"},{"key":"R11-17-20210129","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jgh.12518","article-title":"Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy","volume":"29","author":"Oh","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-17-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/hel.12113","article-title":"Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate","volume":"19","author":"Wu","year":"2014","journal-title":"Helicobacter"},{"key":"R13-17-20210129","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkv089","article-title":"First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori:An open-label, randomized, multicentre clinical trial","volume":"70","author":"Cuadrado-Lav\u00edn","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R14-17-20210129","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/jgh.12983","article-title":"Concomitant and hybrid therapy for Helicobacter pylori infection:A randomized clinical trial","volume":"30","author":"Heo","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R15-17-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/hel.12202","article-title":"Comparison between 10- and 14-day hybrid regimens for Helicobacter pylori eradication:A randomized clinical trial","volume":"20","author":"Metanat","year":"2015","journal-title":"Helicobacter"},{"key":"R17-17-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/hel.12017","article-title":"Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran:A prospective randomized trial","volume":"18","author":"Sardarian","year":"2013","journal-title":"Helicobacter"},{"key":"R18-17-20210129","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clinre.2013.04.003","article-title":"Concomitant, sequential, and hybrid therapy for H pylori eradication: A pilot study","volume":"37","author":"Zullo","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R19-17-20210129","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1099\/jmm.0.072322-0","article-title":"Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication:A prospective randomized study","volume":"63","author":"De","year":"2014","journal-title":"J Med Microbiol"},{"key":"R20-17-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrgastro.2010.210","article-title":"Optimal therapy for Helicobacter pylori infections","volume":"8","author":"Rimbara","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R21-17-20210129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1517\/14656561003657152","article-title":"The sequential therapy regimen for Helicobacter pylori eradication","volume":"11","author":"Gisbert","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"R22-17-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1756283X09343326","article-title":"Sequential therapy for Helicobacter pylori eradication:The time is now!","volume":"2","author":"Vaira","year":"2009","journal-title":"Therap Adv Gastroenterol"},{"key":"R23-17-20210129","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gut.2007.125658","article-title":"The sequential therapy regimen for Helicobacter pylori eradication:A pooled-data analysis","volume":"56","author":"Zullo","year":"2007","journal-title":"Gut"},{"key":"R24-17-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"R25-17-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ajg.2014.26","article-title":"Acomparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection:A randomized multicenter trial","volume":"109","author":"Zhou","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R26-17-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment:A randomized trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter"},{"key":"R27-17-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/hel.12180","article-title":"Review:Efficacy and safety of hybrid therapy for Helicobacter pylori infection:A systematic review and meta-analysis","volume":"20","author":"Wang","year":"2015","journal-title":"Helicobacter"},{"key":"R28-17-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2169\/internalmedicine.54.3442","article-title":"Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication","volume":"54","author":"He","year":"2015","journal-title":"Intern Med"},{"key":"R29-17-20210129","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1136\/bmj.h4052","article-title":"Comparative effectiveness and tolerance of treatments for Helicobacter pylori:Systematic review and network meta-analysis","volume":"351","author":"Li","year":"2015","journal-title":"BMJ"},{"key":"R30-17-20210129","doi-asserted-by":"crossref","first-page":"12954","DOI":"10.3748\/wjg.v21.i45.12954","article-title":"Hybrid therapy for Helicobacter pylori infection:A systemic review and meta-analysis","volume":"21","author":"Hsu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R31-17-20210129","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","article-title":"Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection","volume":"39","author":"Furuta","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"R32-17-20210129","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.clpt.6100043","article-title":"Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H pylori","volume":"81","author":"Furuta","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R33-17-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1517\/17425250903386251","article-title":"CYP2C19 genotypes in the pharmacokinetics\/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection","volume":"6","author":"Yang","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.179803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:38:52Z","timestamp":1623958732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201604200-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,20]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.179803","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,20]]}}}